| Nov 14 |
Opus Genetics reinstated with a Buy at H.C. Wainwright
|
| Nov 12 |
Ocuphire Pharma GAAP EPS of -$0.29 misses by $0.05, revenue of $3.87M beats by $1.57M
|
| Nov 12 |
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
| Oct 25 |
The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics
|
| Oct 23 |
Ocuphire Pharma Merges with Opus Genetics, Renamed Opus Genetics
|
| Oct 22 |
Ocuphire Pharma acquires Opus Genetics
|
| Oct 22 |
Ocuphire Pharma Announces Acquisition of Opus Genetics
|
| Sep 30 |
Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology
|
| Sep 6 |
UPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia
|
| Sep 5 |
Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia
|
